Prelude TherapeuticsPRLD
Market Cap: $267M
About: Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Employees: 128
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
17.77% more ownership
Funds ownership: 62.83% [Q1] → 80.6% (+17.77%) [Q2]
5% more funds holding
Funds holding: 58 [Q1] → 61 (+3) [Q2]
21% less capital invested
Capital invested by funds: $164M [Q1] → $129M (-$34.3M) [Q2]
24% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 21
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Robert Burns 39% 1-year accuracy 56 / 143 met price target | 3%upside $5 | Neutral Reiterated | 15 Aug 2024 |